Tyr591
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr591  -  FLT3 (human)

Site Information
SSDNEyFyVDFREyE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448190

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 5 ) , mutation of modification site ( 2 , 6 , 10 , 11 ) , phospho-antibody ( 1 , 2 , 3 , 7 , 8 , 9 , 11 ) , phosphopeptide mapping ( 5 ) , western blotting ( 1 , 2 , 3 , 7 , 9 )
Disease tissue studied:
leukemia ( 2 , 3 , 7 , 12 ) , acute myelogenous leukemia ( 2 , 3 , 7 , 12 ) , lymphoma ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Kinases, in vitro:
FLT3 (human) ( 6 )
Treatments:
AG1296 ( 8 ) , FL ( 2 , 9 , 11 ) , MLN-518 ( 7 ) , PKC412 ( 3 , 9 )

Downstream Regulation
Effects of modification on FLT3:
enzymatic activity, induced ( 8 ) , molecular association, regulation ( 1 ) , phosphorylation ( 6 , 10 )
Effects of modification on biological processes:
cell growth, altered ( 6 )
Induce interaction with:
Fyn (human) ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
acute myelogenous leukemia ( 4 , 12 )

References 

1

Chougule RA, Kazi JU, Rönnstrand L (2016) FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia. Oncotarget 7, 9964-74
26848862   Curated Info

2

Razumovskaya E, et al. (2009) Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation. Exp Hematol 37, 979-89
19477218   Curated Info

3

Odgerel T, et al. (2008) The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations. Oncogene 27, 3102-10
18071308   Curated Info

4

Irish JM, et al. (2007) Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood 109, 2589-96
17105820   Curated Info

5

Heiss E, et al. (2006) Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood 108, 1542-50
16684964   Curated Info

6

Rocnik JL, et al. (2006) Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood 108, 1339-45
16627759   Curated Info

7

Radomska HS, et al. (2006) Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 203, 371-81
16446383   Curated Info

8

Yang X, et al. (2005) The FLT3 Internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res 65, 7338-47
16103085   Curated Info

9

Kindler T, et al. (2005) Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood 105, 335-40
15345593   Curated Info

10

Kiyoi H, et al. (2002) Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21, 2555-63
11971190   Curated Info

11

Kiyoi H, et al. (1998) Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12, 1333-7
9737679   Curated Info

12

Kiyoi H, et al. (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 11, 1447-52
9305596   Curated Info